Welcome to LookChem.com Sign In|Join Free

CAS

  • or

4645-11-8

Post Buying Request

4645-11-8 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

4645-11-8 Usage

General Description

2-Bromo-6-ethoxy pyridine is a chemical compound with the molecular formula C7H8BrNO. It belongs to the category of chemicals known as heterocyclic aromatic compounds, specifically pyridine and its derivatives. This chemical features a six-membered ring of five carbon atoms and one nitrogen atom, also known as a pyridine ring. It includes bromine and ethoxy functional groups attached at the 2nd and 6th positions of the pyridine ring, respectively. It is used in a wide range of chemical reactions due to its reactivity and versatility. Its usage can range from laboratory research to the synthesis of pharmaceutical drugs and other organic compounds. Always handle it with care as its potential health effects and danger levels under certain conditions are not broadly studied yet.

Check Digit Verification of cas no

The CAS Registry Mumber 4645-11-8 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 4,6,4 and 5 respectively; the second part has 2 digits, 1 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 4645-11:
(6*4)+(5*6)+(4*4)+(3*5)+(2*1)+(1*1)=88
88 % 10 = 8
So 4645-11-8 is a valid CAS Registry Number.
InChI:InChI=1/C7H8BrNO/c1-2-10-7-5-3-4-6(8)9-7/h3-5H,2H2,1H3

4645-11-8Relevant articles and documents

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY

-

Page/Page column 156; 157, (2020/05/15)

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize) the apelin receptor (also referred to herein as the APJ receptor; gene symbol APLNR). This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which a decrease in APJ receptor activity (e.g., repressed or impaired APJ receptor signaling; e.g., repressed or impaired apelin-APJ receptor signaling) or downregulation of endogenous apelin contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition. Non-limiting examples of such diseases, disorders, or conditions include: (i) cardiovascular disease; (ii) metabolic disorders; (iii) diseases, disorders, and conditions associated with vascular pathology; and (iv) organ failure; (v) diseases, disorders, and conditions associated with infections (e.g., microbial infections); and (vi) diseases, disorders, or conditions that are sequela or comorbid with any of the foregoing or any disclosed herein. More particular non-limiting examples of such diseases, disorders, or conditions include pulmonary hypertension (e.g., PAH); heart failure; type II diabetes; renal failure; sepsis; and systemic hypertension.

Novel synthesis method for ortho-alkane superseded pyridine

-

Paragraph 0018; 0019; 0020; 0021, (2017/07/19)

The invention relates to a novel synthesis method for ortho-alkane superseded pyridine. According to the method, ortho halogenated pyridine serves as raw materials, the ortho halogenated pyridine and corresponding alcohol react to obtain the ortho-alkane superseded pyridine under the action of sodium hydroxide. The reaction has universality for the ortho halogenated pyridine, and the method is simple and practical. Influence of consumption of the sodium hydroxide on mono-substitution and di-substitution in the reaction is inspected, alkoxy mono-substitution products and alkoxy di-substitution production are acquired, and a novel simply-operated, economical and favorable process for synthesis ortho-alkane superseded pyridine is provided.

Metalloprotease inhibitors

-

, (2008/06/13)

Compounds of formula (I) and pharmaceutically-acceptable derivatives thereof, are matrix metalloprotease inhibitors, useful in treatment of conditions mediated by matrix metalloproteases, such as chronic dermal ulcers.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 4645-11-8